Level C· Early human research exploring benefitsCase Report / SeriesPubMedOpen access

The use of regenerative technologies for treatment of delayed fracture union in patient with menopausal osteoporosis.

Maslennikov S., Kozhemyaka M., Golovakha M.

Case Report / Series on Systemic / IV, published in Prz Menopauzalny (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Prz Menopauzalny (2025)
Country
Poland
Reported sample size
—
Source database
PubMed
PMID
40777870
PMCID
PMC12327223
DOI
10.5114/pm.2025.152148

Abstract (original English)

Delayed fracture union is a common complication in orthopedic practice, particularly in patients with osteoporosis. Advances in regenerative medicine, including mesenchymal stem cells (MSCs) within the stromal-vascular fraction, have introduced novel therapeutic approaches to address this challenge. This case describes a patient with postmenopausal osteoporosis and a congenital anomaly of the left lower limb who sustained a proximal tibial fracture with fragment displacement. Osteoporosis therapy was initiated, and the fracture was managed using external fixation and compression. Despite an improvement in bone mineral density over an eight-month period, radiographic assessment revealed no evidence of fracture union. Consequently, local administration of MSCs combined with needling at the fracture site was performed, followed by a series of autologous concentrated plasma (ACP) injections. Within three months, radiographic signs of bone callus formation were observed, ultimately leading to complete fracture union six months after the initiation of regenerative therapy. Although the limited number of cases in our clinic prevents definitive conclusions regarding the primary contributing factor in fracture healing, existing literature suggests that the mobilization of endogenous resources at the fracture site in high concentrations promotes tissue regeneration. This process is furth

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research